Comprehensive Management of Hypertension, Heart Failure, and Atrial Fibrillation

Introduction to Guideline-Directed Therapy

The American College of Cardiology recommends treating patients with hypertension, heart failure, and atrial fibrillation to a blood pressure goal of <130/80 mmHg using ACE inhibitors or ARBs as first-line therapy, with the addition of beta-blockers for heart failure and rate control, and initiation of SGLT2 inhibitors for heart failure regardless of ejection fraction 1, 2
The European Heart Journal suggests that this target applies across all CKD stages and provides cardiovascular and mortality benefits demonstrated in the SPRINT trial, with a strength of evidence level of I (high) 4, 5

The American College of Cardiology recommends starting an ACE inhibitor as the first-line agent for CKD stage 3, which slows kidney disease progression and provides heart failure benefits, with a strength of evidence level of I (high) 1, 2
If ACE inhibitor is not tolerated, the American College of Cardiology suggests switching to an ARB as the alternative, with a strength of evidence level of IIa (moderate) 1, 2

The European Heart Journal recommends adding a beta-blocker for heart failure management, which also provides rate control for atrial fibrillation, with a strength of evidence level of I (high) 4, 5
The European Heart Journal suggests initiating an SGLT2 inhibitor regardless of left ventricular ejection fraction to reduce HF hospitalization and cardiovascular death, with a strength of evidence level of I (high) 4, 5

The European Heart Journal recommends calculating the CHA₂DS₂-VASc score to determine the need for anticoagulation, with a strength of evidence level of I (high) 4, 5
The European Heart Journal suggests initiating oral anticoagulation with a direct oral anticoagulant rather than warfarin, with a strength of evidence level of I (high) 4, 5

The European Heart Journal recommends blood pressure lowering to reduce AF recurrence and progression as well as prevent adverse cardiovascular events, with a strength of evidence level of I (high) 4, 5
The European Heart Journal suggests effective glycemic control if diabetic to reduce AF burden, recurrence, and progression, with a strength of evidence level of IIa (moderate) 4, 5

The American College of Cardiology recommends checking serum creatinine, potassium, and eGFR within 2-4 weeks after starting or titrating ACE inhibitor/ARB, with a strength of evidence level of IIa (moderate) 3
The European Heart Journal suggests monitoring electrolytes regularly with diuretic therapy and mineralocorticoid receptor antagonist use, with a strength of evidence level of IIa (moderate) 6

The American College of Cardiology recommends not discontinuing ACE inhibitor/ARB for modest creatinine increases (<30% rise), as these medications provide long-term kidney and cardiovascular protection, with a strength of evidence level of I (high) 3
The European Heart Journal suggests not using symptom-based questionnaires alone for screening obstructive sleep apnea in AF patients, with a strength of evidence level of IIb (low) 4, 5